This website uses cookies to enhance the user experience.
N

NORSK MEDISINSK SYKLOTRONSENTER AS986 358 692

Process industry
Limited company
Ullernchausséen 64 0379 OSLO, Norge

NORSK MEDISINSK SYKLOTRONSENTER AS

Velkommen til Syklotronsenteret | Syklotronsenteret - Norsk medisinsk syklotronsenter AS

Keywords

productionpharmaceuticalsantiserablood fractionsvaccineshomeopathic preparationscontraceptive productsbone buildingdiagnostic preparationspregnancy testsbiotechnological medicinescotton woolgasbandagesdressings

Links

Organization

Chairman of the board
Years since formation
20 years
since Mar 16, 2004
Type
Limited company
VAT registered
Yes
Number of employees
55

Ownership

Number of shares and share classes
500
1 share class
Total number of shareholders
3
companies
Belongs to group of

Financials

Total operating income 2023
91,600,367
NOK
Annual total result 2023
-11,659,592
NOK
Total equity 2023
17,949,061
NOK
Last update: Nov 14, 2024

Management

Management / administration

NameRoleShares
Managing Director/CEO-

Board

NameRoleShares
Board Member-
Board Member-
JD
Board Member-
Board Member-
ResignedChairman-
Board Member-
Deputy Chair-

Others

NameRoleShares
P
PRICEWATERHOUSECOOPERS AS
Auditor-
A
AZETS INSIGHT AS
Accountant-
Last update: Jun 26, 2024

Ownership

Company shareholders

NameShare classNumber of sharesShare
O
OSLO UNIVERSITETSSYKEHUS HF
Ordinary shares
350
70 %
U
UNIVERSITETET I OSLO
Ordinary shares
100
20 %
Ordinary shares
50
10 %

Shares owned by the NORSK MEDISINSK SYKLOTRONSENTER AS

NameShare classNumber of sharesShare
R
RADFARMA AS
Ordinary shares
450
45 %
Last update: May 24, 2024

Group structure

Financials

in NOK

Summary

Year202320222021
Total operating income
91,600,367
82,525,758
94,253,445
Annual Total Result
-11,659,592
-455,850
1,681,703
Total assets
75,998,538
68,276,790
66,259,993
Total liabilities
58,049,477
38,668,137
36,195,491
Total equity
17,949,061
29,608,653
30,064,503

P&L

Year202320222021
Total operating income
91,600,367
82,525,758
94,253,445
Total operating costs
105,237,122
82,387,826
91,807,317
Operating result
-13,636,755
137,932
2,446,128
Financial income/costs
-591,638
-166,050
82,642
Profit before tax
-14,228,393
-28,118
2,528,770
Total tax & extraordinary income/cost
-2,568,801
427,732
847,067
Annual Total Result
-11,659,592
-455,850
1,681,703

Balance overview

Year202320222021
Total fixed assets
48,017,188
44,180,714
38,129,675
Total current assets
27,981,350
24,096,076
28,130,318
Total assets
75,998,538
68,276,790
66,259,993
Short term debt
29,789,586
21,200,120
22,483,764
Long term debt
28,259,891
17,468,017
13,711,727
Total liabilities
58,049,477
38,668,137
36,195,491
Contributed capital
1,993,340
1,993,340
1,993,340
Retained earnings
15,955,721
27,615,313
28,071,163
Total equity
17,949,061
29,608,653
30,064,503
Total equity and liabilities
75,998,538
68,276,790
66,259,994

Classification

Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
1120
Public incorporated enterprises, owned by central government
Standard industrial classification
C
Main industrial area
Manufacturing
21
Activity
Manufacture of basic pharmaceutical products and pharmaceutical preparations
21.2
Main industrial group
Manufacture of pharmaceutical preparations
21.20
Industrial group
Manufacture of pharmaceutical preparations
21.200
Industrial group
Manufacture of pharmaceutical preparations